SCHEMBL6921464

SCHEMBL6921464

Cc1ccc(Cl)cc1CNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.50
GAA P10253 1/20 0.48
KDM4A O75164 1/20 0.45
P2RX7 Q99572 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
MAPT P10636 1/20 0.43
XBP1 P17861 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DRD2 P14416 1/20 0.43
ANO1 Q5XXA6 1/20 0.42
SETDB1 Q15047 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23997640 0.90 IDO1 (0.52) IDO1GAAKDM4AP2RX7ALDH1A1
SCHEMBL27988801 0.88 IDO1 (0.53) IDO1GAAKDM4AP2RX7ALDH1A1
SCHEMBL23979460 0.87 IDO1 (0.47) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL3734185 0.87 ANO1 (0.51) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL23979459 0.86 ABL1 (0.48) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL4757294 0.86 GAA (0.49) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL21987969 0.86 IDO1 (0.48) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL29793580 0.86 GAA (0.49) IDO1GAAKDM4AALDH1A1HPGD
SCHEMBL6919952 0.86 IDO1 (0.51) IDO1GAAKDM4AP2RX7ALDH1A1
SCHEMBL4296419 0.85 IDO1 (0.46) IDO1GAAKDM4AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI IDO1 2641/4885GAA 4559/4885KDM4A 4206/4885
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B IDO1 1325/4885GAA 4374/4885KDM4A 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.